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Abstract: Multiple myeloma (MM) is a neoplastic disorder. It results from proliferation of clonal plasma cells in bone marrow with 
production of monoclonal proteins, which are detectable in serum or urine. MM is clinically characterized by destructive bone lesions, 
anemia, hypercalcemia and renal insufficiency. Its prognosis is severe, with a median survival after diagnosis of approximately 3 years 
due to frequent relapses. Treatments for patients with relapsed/refractory MM include hematopoietic cell transplantation, a rechallenge 
using a previous chemotherapy regimen or a trial of a new regimen. The introduction of new drugs such as thalidomide, lenalidomide 
and bortezomib has markedly improved MM outcomes. When relapse occurs, the clinician’s challenge is to select the optimal treat-
ment for each patient while balancing efficacy and toxicity. Patients with indolent relapse can be first treated with a 2-drug or a 3-drug 
combination. Patients with more aggressive relapse often require therapy with a combination of multiple active agents. Autologous stem 
cell transplantation should be considered as salvage therapy at first relapse for patients who have cryopreserved stem cells early in the 
disease course. The aim of this review is to provide an overview on the pharmacological and molecular action of treatments used for 
patients with relapsed/refractory multiple myeloma.
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Introduction
Multiple myeloma (MM) is a neoplastic disorder due 
to the proliferation of clonal plasma cells in bone mar-
row (BM) with production of monoclonal proteins. 
These proteins are detectable in serum and/or urine, 
and MM is clinically characterized by destruc-
tive bone lesions, anemia, hypercalcemia and renal 
insufficiency.1 Its prognosis is severe, with a median 
survival after diagnosis of approximately 3 years. It 
accounts for 1.5%–2% of all cancer deaths.1 In the 
last decade, the introduction of immunomodulatory 
drugs (IMIDs) such as thalidomide and lenalidomide, 
and of new front-line agents such as the proteasome 
inhibitor bortezomib, has significantly improved 
overall survival. Still, not all patients respond to these 
new drugs, and the development of drug resistance is 
common.
The term “relapsed MM” describes subjects who 
have previously achieved at least a minor response 
after salvage therapy, but then experience progres-
sive disease, while with “refractory MM”, subjects 
are either unresponsive to salvage therapy or are 
progressing within 60 days of the last treatment.2 
Although conceptually distinct, in clinical practice 
these 2 conditions may be grouped with the term 
relapsed/refractory MM and the approach to these 
patients still represents a challenge for specialists.1
The underlying biological mechanisms of relapsed 
or refractory MM have been recently clarified. For 
instance, the existence of minor sub-clones that can 
survive chemotherapy and thus become a reservoir 
for relapse or resistance has been demonstrated.3 The 
genetic instability of aggressive MM sub-clones and 
the selective pressures introduced by therapy during 
the course of the disease are currently considered the 
2 primary factors conditioning relapse or resistance.4
Traditionally, relapsed/refractory MM has been 
treated with standard combinations of alkylating 
agents, anthracyclines and corticosteroids, with or 
without hematopoietic stem cell rescue.5,6 The new 
IMIDs and proteasome inhibitors have not only sig-
nificantly prolonged the overall survival in relapsed/
refractory patients, but also have improved the rate, 
the depth and the duration of responses in front-line 
therapy.7–9 The impact of the depth of response on 
survival in the relapse setting is still controversial. 
Based on recent evidence, complete response (CR) 
seems to be the only condition linked with long-term 
remission and prolonged survival, especially when 
supported by multi-parameter flow cytometry or 
molecular studies.10,11 Instead, near-CR, very good 
partial remission (VGPR) and partial remission (PR) 
all seem to have virtually identical outcomes.10,11
The aim of this review is to provide an overview 
of the pharmacological and molecular action of the 
drugs used to treat relapsed/refractory MM, and of 
the available approaches for tailoring management of 
such patients.
current Treatment Options
Although substantial progress has been made in 
recent years, MM still remains an incurable disease in 
most cases, due to frequent relapses. However, sev-
eral new drugs active in relapsed/refractory MM are 
now available. When dealing with this set of patients, 
the challenge is to select the optimal treatment, taking 
into account efficacy and toxicity of the drug and both 
disease- and patient-related factors (Fig. 1).
Chemotherapy and transplantation
The use of conventional or high-dose chemother-
apy is a long-standing approach to salvage therapy 
in patients with relapsed MM. In the past, various 
standard chemotherapy-based regimens have been 
used, among which the most widely employed are: 
(i) high dose melphalan, (ii) high dose prednisolone, 
(iii) high dose dexamethasone, (iv) vincristine, doxo-
rubicin and pulsed high dose dexamethasone (VAD), 
(v) vincristine, melphalan, cyclophosphamide and 
prednisone (VMPC) alternating with vincristine, 
carmustine, doxorubicin, prednisone (VBAP), (vi) 
doxorubicin, vincristine, dexamethasone, etopo-
side and cyclophosphamide (CEVAD), (vii) cispla-
tin, doxorubicin, cyclophosphamide and etoposide 
(DTPACE), and (viii) dexamethasone, cyclophosph-
amide, etoposide and cisplatin (DCEP). The overall 
rates of response to salvage combination chemo-
therapy range between 30% and 60%, with morbid-
ity and mortality rates related to the intensity of the 
therapy itself.12
Single or double autologous stem cell transplan-
tation (ASCT) remains the milestone for a front-
line approach in MM patients eligible for high-dose 
therapy, and the second ASCT represents a safe option 
for MM patients who were firstly treated with single 
ASCT.13–16 Although data support the use of a late 
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When and how to treat relapsed/refractory multiple myeloma
Consider treatment if CRAB symptoms (elevated Calcium, Renal impairment, Anemia, 
and Bone lesions) or increase of paraprotein (monoclonal component >1g/dL; Bence Jones
Protein >500 mg/day; serum free light chain >200 mg/L
Consider treatment related conditions
– Prior drug exposure
– Ongoing toxicity from prior therapy
Consider patient related conditions
– Poor performance
– Poor renal function
– Poor hematopoietic reserve
Consider disease related conditions
Quality and duration of response to initial TX
1. Indolent and slow
2. Aggresive and rapid
– Initial therapy with 
IMIDs
– Renal dysfunction
– High risk genetics:
1q+; del17p; t(4;14)
– Initial therapy with 
bortezomib
– Polyneuropathy
– Good risk
– Prior bortezomib and or 
lenalidomide
– Cytopenia
– Severe renal impairment
Lenalidomide
Based salvage
Bortezomib
Based salvage
Thalidomide
Based salvage
1. Indolent and slow
Combinations of
lenalidomide/bortezomib
and other
chemoagents
– DCEP
– DT-PACE
– Additional stem cells in store
– Long remission after 1st transplant
– Cytopenia
Chemotherapy
Based regimens
Chemotherapy +
Novel agent
Transplant
Based regimens
2. Aggressive and rapid
Transplant
Based regimens
– Stem cell
   transplantation if
   deffered in firstline
   treatment
Figure 1. The clinical picture of relapsed multiple myeloma ranges from an asymptomatic form to very aggressive disease. Relapsing patients with multiple 
myeloma should be treated at the appearance of the typical clinical manifestations of multiple myeloma which are summarized by the CRAB symptoms 
(elevated Calcium, Renal impairment, Anemia, and Bone lesions), or when monoclonal protein in serum or urine has a significant growth (M spike .1 g/dL, 
Bence Jones protein [BJP] . 500 mg/day, or serum free light chain . 200 mg/dL). The treatment armamentarium in indolent or slow relapsing/refractory 
patients include, thalidomide, lenalidomide and bortezomib. Pomalidomide is considered in patients who have received at least two prior therapies, includ-
ing lenalidomide and bortezomib, demonstrating disease progression.
Disease-, patient- and treatment-related conditions should be considered in the therapeutic management of relapsed/refractory multiple myeloma.
The disease-related factors include the quality and duration of response to previous therapies. If the relapse occurs after a long remission and treatment-
free period, it is possible to consider the rechallenge of the same treatment but, if it occurs earlier (6–12 months) or while the patient is still undergoing 
treatment (which indicates aggressive, relapsed and refractory disease), the use of an alternative regimen should be considered. Cytogenetic abnormali-
ties may indicate high-risk disease, which requires a different approach from that used in ‘slowly’ relapsing patients. Bortezomib can overcome the poor 
prognosis of patients with unfavorable chromosomal abnormalities, such as the del(13q14) and t(4:14) mutations. There are also initial data suggesting 
that high doses of bortezomib-based treatment may be effective in patients with the del(17p) mutation, which is usually associated with refractoriness to 
therapy.
The patient-related factors include pre-existing toxicities, comorbidities, the quality of life, age and performance status. Among the new drugs, bortezomib 
and thalidomide are not excreted renally, which makes them better for patients with renal impairment than lenalidomide, which is renally excreted and 
therefore requires dose adjustments. The use of thalidomide and bortezomib can lead to neuropathy in up to 80% of previously treated patients, whereas 
neuropathy is less frequent in patients treated with lenalidomide-based regimens, thus making them a reasonable choice in patients with pre-existing 
neuropathies. venous thromboembolism and occasional thrombotic events have been reported in patients treated with IMIDs, especially when combined 
with pulsed dexamethasone instead of Bortezomib which seems. In addition lenalidomide seems to be associated with Myelosuppression.
The treatment related conditions include prior drug exposure and toxicities from prior therapy.
The challenge when treating patients with relapsed or refractory disease is to select the optimal treatment by balancing efficacy, toxicity and severity of 
relapse.
1.  when treating indolent or slow relapse the treatment options include: lenalidomide based salvage therapy if patient have been previously exposed to 
bortezomib therapy, have history of polyneuropathy or have cytogenetic standard risk; bortezomib based salvage therapy if patient has been exposed 
to IMIDs, have renal failure or unfavorable chromosomal abnormalities; thalidomide based salvage therapies are indicated in presence of previous 
treatment with bortezomib or lenalidomide, cytopenia or severe renal impairment. Stem cell transplantation may be considered if deferred in first line 
therapy
2.  Aggressive and rapid relapse requires an immediate treatment, which is likely a combination therapy including treatment with chemotherapy based 
regimens, chemotherapy in combination with novel agents (lenalidomide or bortezomib) or transplant based regimen.
second ASCT in patients with relapsed/progressive 
MM,17 researchers of the European Group for Blood 
and Marrow Transplantation found that outcomes 
were better when the second ASCT was performed 
before relapse, within 6–12 months from the first 
ASCT.18 The role of allogenic stem cell transplanta-
tion, potentially curative for myeloma, is controver-
sial in relapsed/refractory MM.12
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Immunomodulatory drugs (IMIDs)
Thalidomide
Thalidomide (α-N-phthalimido-glutarimide) repre-
sents the progenitor of IMIDs and is a synthetic deriva-
tive of glutamic acid. It was initially introduced in 1956 
as a sedative hypnotic. Subsequently, it was observed 
that the drug can potentiate the immune response by 
restoring dendritic cell function and inhibiting T cell 
regulatory activity, leading to the activation of T lym-
phocytes and natural killer T (NKT) cells via interleukin 
2 (IL-2) and interferon gamma (IFNγ) and activation 
of natural killer (NK) cells. The anti-tumoral activity 
of IMIDs consists in the disruption of the interactions 
between neoplastic clones, the BM micro-environ-
ment and anti-angiogenic activity.19 The mechanism 
of action of thalidomide is based on apoptosis of neo-
plastic cells by down-regulation of anti-apoptotic pro-
teins via the caspase 8-mediated pathway.19
Thalidomide alone has been reported to induce par-
tial remission in 50% of newly diagnosed patients, a rate 
that increases to 60%–70% when used in combination 
with oral dexamethasone. In 2006, the US Food and 
Drug Administration approved thalidomide in combi-
nation with dexamethasone for the treatment of newly 
diagnosed MM patients. When used in patients with 
relapsed/refractory MM, several studies have demon-
strated that it leads to response rates of 25%–35%.20–22 
It is also used as maintenance therapy in patients with 
progressive MM after SCT.22 In the relapsed/refrac-
tory MM setting, thalidomide used in association with 
dexamethasone and/or cyclophosphamide shows even 
higher response rates.23 Also the combination of tha-
lidomide and conventional chemotherapy is clearly 
active, leading to overall response rates of 60%–75%, 
with CR rates of approximately 20% in a number of 
early phase I/II studies.24,25
Lenalidomide
Lenalidomide (Revlimid®; Celgene, NJ, USA) is an 
oral derivative of thalidomide with a different toxicity 
profile, as well as different immunomodulatory, anti-
angiogenic and anti-neoplastic activity and different 
anti-inflammatory effects.7,26 In 2006, the US Food and 
Drug Administration approved lenalidomide for use 
in combination with dexamethasone in patients with 
MM who have received 1 prior therapy. In 2 parallel 
trials, MM-009 and MM-010 lenalidomide was used 
at the dose of 25 mg on days 1 to 21 of a 28-day 
schedule, and dexamethasone was given on days 1–4, 
9–12 and 17–20 for the first 4 cycles as intravenous 
pulse therapy, with the dose being reduced for subse-
quent cycles.26 These observations provided evidence 
that treatment with lenalidomide plus dexametha-
sone leads to good responses, in the absence of dis-
ease progression and toxicity, thus obtaining a deeper 
remission and overall greater clinical advantages. 
Further trials confirmed the efficacy of lenalidomide 
in relapsed/refractory MM26–30 as well as in other 
hematological malignancies.31–33
Pomalidomide
The third available IMID, pomalidomide (CC4047), 
has been developed to improve the clinical effi-
cacy and reduce the toxicity of its parent molecule 
thalidomide. In fact, it has a good toxicity profile. 
Neutropenia and thromboembolic complications 
are as frequent as with the other IMIDs, whereas 
other side effects such as neuropathy are rare.7 
Pomalidomide was shown to be more effective than 
thalidomide in inhibiting the proliferation of malig-
nant B cells in vitro, while in vivo increases the 
serum levels of IL-2 receptors and IL-12, and may 
promote the switch to an effector T-cell phenotype 
as well as the inhibition of osteoclast differentiation, 
reducing the destructive effects of MM in the bone 
microenvironment.7,34
Due to its recent introduction, pomalidomide has so 
far only been investigated in phase I and phase II trials 
involving heavily pre-treated patients. In 2013, the 
Food and Drug Administration approved pomalido-
mide for the treatment of patients with MM who have 
received at least 2 prior therapies, including lenalido-
mide and bortezomib, and have demonstrated disease 
progression on or within 60 days of completion of the 
last therapy. Pomalidomide at doses of 2 mg/day (d) 
has demonstrated excellent activity in patients with 
MM who failed to respond after treatment with lenali-
domide and bortezomib.35–37 Myelosuppression was 
the most common toxicity. Pomalidomide overcomes 
resistance in myeloma refractory to both lenalidomide 
and bortezomib.
Proteasome inhibitors
Bortezomib
Bortezomib (PS-341) is the prototype proteasome 
inhibitor. It has potent anti-myeloma activity both 
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when used alone and in combination with other 
drugs. In 2008, the US Food and Drug Administration 
approved bortezomib for the treatment of patients 
with MM.
Bortezomib was previously approved in 2003 for 
the treatment of refractory MM and in 2005 for the 
treatment of patients with MM who had received at 
least 1 prior therapy. The ubiquitin proteasome sys-
tem is a multi-catalytic proteinase complex that, in 
order to maintain cell homeostasis, degrades a great 
variety of protein substrates both in normal and 
transformed cells. Consequently, proteasome inhibi-
tion affects a wide range of cell functions such as 
cell cycle regulation and apoptosis.5 Cancer cells, 
especially in MM, seem to be highly dependent on 
proteasome-homeostatic pathways. Furthermore, 
bortezomib stabilizes the nuclear factor kappa light 
chain-enhancer of activated B cells (NF kappa B) 
and up-regulates anti-apoptotic factors in tubular 
cells.5,12
A further large randomized trial in patients with 
relapsed/refractory myeloma, who had received no 
more than 3 previous treatment regimens, demon-
strated the superiority of bortezomib given intrave-
nously on days 1, 4, 8 and 11 of a 21-day cycle 
over pulse dexamethasone. The overall response 
rate was 38%, and the median time to progression 
(TTP) was 6.2 months, compared to only 18% and 
3.5 months with dexamethasone.38 Bortezomib 
showed a minimal BM toxicity, ease of use in the 
case of renal failure, and absence of thrombogenic-
ity. Bortezomib does not undergo renal clearance, 
and therefore needs no dose adjustments in patients 
with renal disease. The activity of bortezomib in 
patients with MM and renal insufficiency has been 
demonstrated in different studies.39,40 Bortezomib 
seems to overcome the poor prognosis of patients 
with unfavorable chromosomal abnormalities, such 
as the del(13q14) and t(4:14) mutations and there 
are initial data suggesting effectiveness at high 
doses even in patients with the del(17p) mutation, 
a negative prognostic factor associated with refrac-
toriness and worse prognosis. Recent studies pro-
vide evidence that bortezomib at high doses may 
be of interest in patients with del(17p) mutation.41,42 
In conclusion several authors have shown efficacy 
of bortezomib alone or in combination in relapsed 
refractory MM.42–49
Carfilzomib
A second-generation proteasome inhibitor PR-171 
(carfilzomib) with different functional capacities has 
been developed. Carfilzomib is able to irreversibly 
inhibit the chymotryptic activity of the proteasome. 
Clinical studies have shown that carfilzomib has long-
lasting anti-cancer activity in patients with relapsed/
refractory MM, even those previously treated with 
bortezomib. Ongoing phase II trials have shown an 
overall response rate of 23.7% with a median dura-
tion of response of 7.8 months, and a median overall 
survival of 15.6 months. The safety profile is good, 
with adverse events manageable without giving rise 
to cumulative toxicities. The lasting responses and 
the drug’s acceptability demonstrate the potential of 
carfilzomib to offer a significant clinical benefit even 
in a heavily pre-treated population.50 In 2012, the US 
Food and Drug Administration approved carfilzomib 
for the treatment of patients with MM who have 
received at least 2 prior therapies, including bort-
ezomib and IMIDs, and have demonstrated disease 
progression on or within 60 days of the completion 
of the last therapy. In an open-label, single-arm, mul-
ticentre pilot phase II study of carfilzomib involving 
46 patients with relapsed and refractory MM after $2 
previous therapies, the best overall response rate 
was 16.7%, with a median duration of response of 
7.2 months.51
Other proteasome inhibitors are being devel-
oped with different spectrum of activity (eg, pan-
proteasome inhibition with NPI-0052) and oral 
formulation.
IMIDs combined with bortezomib
New combinations of an IMID and bortezomib 
have been introduced, based on recent discover-
ies concerning the fundamental molecular mecha-
nisms underlying MM cell growth and survival. 
Both IMIDs and bortezomib have significant activ-
ity against MM when used as single agents, so the 
challenge is to demonstrate whether their combina-
tion may reciprocally enhance their activity, theoreti-
cally reducing the risk of the emergence of resistant 
clones. The rationale for combining an IMID and 
bortezomib is related to their complementary mecha-
nisms of action. However, as cumulative toxicity is a 
concern, various groups are evaluating the impact of 
other bortezomib-based combination therapies, such 
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as the association with thalidomide and dexametha-
sone (BTD).
The combination of bortezomib (Velcade) , tha-
lidomide and dexamethasone (VTD) was compared 
with that of thalidomide and dexamethasone (TD) 
before ASCT in a phase III trial by the GIMEMA 
group.52 The 241 patients randomized to the VTD 
arm received standard-dose bortezomib with dexam-
ethasone 40 mg on days 1, 2, 4, 5, 8, 9, 11 and 12, 
and thalidomide 200 mg/day for 63 days, whereas 
the 238 randomized to the TD arm received thalido-
mide 200 mg/day and dexamethasone 40 mg on days 
1–4 and 9–12 of each 21-day cycle. As 6 patients 
withdrew their consent before starting treatment, the 
intention-to-treat analysis was based on 236 patients 
treated with VTD and 238 receiving TD. After induc-
tion therapy, a CR or near-CR was achieved in 31% of 
VTD and 11% of TD treated patients. VTD induction 
therapy before double ASCT significantly improved 
the rate of CR or near-CRs, and now represents a 
new standard of care for MM patients eligible for 
transplantation.
Another study aimed to assess efficacy, safety, and 
the reversal of renal impairment (RI) in previously 
untreated MM patients who received a combination 
of bortezomib, melphalan, prednisone and thalido-
mide followed by maintenance treatment with bort-
ezomib and thalidomide (VMPT-VT) or bortezomib, 
melphalan and prednisone (VMP). There were statis-
tically significant improvements in overall response 
rates and progression-free survival in the VMPT-VT 
arm across the renal cohorts, except in the group of 
patients with severe RI. In the VMPT group, severe 
RI reduced OS. RI was reversed in 16/63 patients 
receiving VMPT-VT (25.4%) and 31/77 receiving 
VMP (40.3%). VMPT-VT was superior to VMP in the 
patients with normal renal function but not in patients 
with severe renal insufficiency.53
Under Research Drugs
Histone deacetylase inhibitors
Panobinostat (LBH589) and vorinostat are his-
tone deacetylase (HDAC) inhibitors, a new class of 
anti-myeloma agents. Inhibition of HDAC leads to 
histone hyperacetylation and structural alterations 
in chromatin causing growth arrest differentiation 
and/or apoptosis in tumor cells. HDAC inhibitors 
induce transcriptional modulations in 7%–10% of the 
genes in malignant cell lines as shown by microar-
ray-based studies, by acetylating histone and non-
histone proteins. HDAC inhibitor-induced cell death 
is one of the main mechanisms of inhibition of the 
survival of myeloma cells.6 In MM cells treated with 
an HDAC inhibitor, extrinsic and intrinsic apoptotic 
pathways, as well as non-apoptotic cell death such 
as autophagy, have been observed. The intrinsic 
apoptotic pathway is mediated by the mitochondria, 
and the pro-apoptotic signals result in the release of 
mitochondrial inter-membrane proteins such as cyto-
chrome c (cyto-c), apoptosis-inducing factors (AIFs) 
and the second mitochondria-derived activator of 
caspase (Smac). HDAC inhibitors induce cell cycle 
arrest in the G1/S phase. The events in the G1 phase 
are coordinated by the three early G1 D cyclins (1, 2 
and 3) and their associated cyclin-dependent kinases 
(CDKs) 4/6 (G1 progression) and CDK 2 (G1/S 
transition).6
A number of clinical trials of HDAC inhibitors 
alone or in combination with other anti-myeloma 
agents are ongoing. Phase I trials have shown 
that HDAC inhibitors are well tolerated by MM 
patients, although phase II trials have found that 
the activity of HDAC inhibitors as single agents 
is limited. However, when combined with dexam-
ethasone and/or bortezomib, the results are more 
promising, even in patients with refractory and/or 
relapsed MM.54 Panobinostat (LBH589) and vor-
inostat have shown to be promising in combination 
with current treatment options, and panobinostat is 
currently being tested in a large, randomized phase 
III trial.6
Immune-based therapies
Monoclonal antibody therapy is a further option for 
MM patients. Elotuzumab is a humanized monoclonal 
IgG1 antibody directed against CS-1, a cell surface 
glycoprotein that is highly and uniformly expressed on 
MM cells. Elotuzumab induces significant antibody-
dependent cytotoxicity against primary MM cells in the 
presence of peripheral lymphocytes and, in combina-
tion with lenalidomide and low-dose dexamethasone, 
has led to promising results.55 Another 2 agents of the 
same class have also showed promise: lorvotuzumab 
(anti-CD56) in combination with lenalidomide and 
dexamethasone, and mapatumumab (anti-Trail-R1) 
in combination with bortezomib.56
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Alkylators
Among alkylating agents, bendamustine is struc-
turally similar to purine analogues, and it has been 
found to be active in MM patients. The final results 
of a phase I/II study of bendamustine combined with 
lenalidomide and dexamethasone in patients with 
relapsed/refractory MM have been recently published, 
showing that this combination has anti-myeloma 
activity with relatively little toxicity in previously 
treated MM patients.57,58
safety
The frequency and severity of IMID side-effects 
are dose-related and time-dependent, and should 
be graded based on the National Cancer Institute 
Common Toxicity Criteria for Adverse Events. 
Venous thromboembolism (VTE) and occasional 
thrombotic events have been reported in patients 
treated with thalidomide, especially when thalido-
mide is combined with pulsed dexamethasone (TD).59 
The thrombogenic effects are likely due to many fac-
tors such as a transient reduction in soluble throm-
bomodulin levels during the first month of therapy, 
the restoration of endothelial cell PAR-1 expression 
after damage by cytotoxic agents such as doxorubicin 
and the activation of pro-coagulant tissue factor (TF) 
induced by phosphatylserine on the apoptotic cell 
membrane.59–62
Although structurally related to thalidomide, 
lenalidomide and pomalidomide are relatively more 
potent and show a different toxicity profile. Sedation, 
constipation and neuropathy, often associated with 
thalidomide, are not commonly seen with lenalido-
mide and pomalidomide, but the risk of developing 
thromboembolic events seems to be similar to that 
attributed to thalidomide combinations. Also, in the 
case of lenalidomide, the combination of dexam-
ethasone seems to increase the risk of thromboem-
bolic complications.59 The dose-limiting side effect 
of lenalidomide in phase I studies is myelosuppres-
sion (grade 3–4 neutropenia and thrombocytopenia). 
Although this is the most frequent adverse event, it can 
be effectively managed by means of dose reductions 
or discontinuation of the drug, although granulocyte 
colony-stimulating factor (G-CSF) or erythropoietin 
may be needed in more severe cases.63 The devel-
opment of second primary malignancies (SPMs) 
among patients treated with lenalidomide is still 
controversial. On one hand, an increased incidence of 
SPM has been observed in MM patients after lenali-
domide therapy, as compared to control patients (3.98 
per 100 patient-years vs. 1.38 per 100 patient-years).64 
Particularly, acute myeloid leukemia (AML) seems to 
be the main SPM in MM patients treated with lenali-
domide, with an increase of incidence reaching 11.5-
fold as compared to general population, as reported 
by data analysis from a Swedish register.64 On the 
other hand, other researchers found no differences in 
the incidence of SPM in myelodysplastic syndrome 
patients treated with lenalidomide as compared to a 
historic group with myelodysplastic syndrome not 
treated with lenalidomide.65 Indeed, the PFS benefit 
obtained using lenalidomide maintenance treatment 
is reckoned to outweigh the increased risk of SPM.66 
Finally, melphalan could also be responsible for the 
increased risk of hematological malignancies, thus 
further complicating data interpretation.65 Similarly, 
Palumbo et al66 have recently stated that the PFS ben-
efit obtained using lenalidomide maintenance treat-
ment outweighs the increased risk of SPM; moreover, 
in patients with relapsing/refractory MM, the number 
and types of SPM do not seem to affect the drug’s 
risk/benefit profile.
Bortezomib toxicity is characterized by nau-
sea, diarrhea, cyclic reversible thrombocytopenia, 
fatigue, and peripheral neuropathy. Peripheral neu-
ropathy occurs in about one-third of patients and may 
have a painful component. It improves or resolves 
in a high proportion of patients, although recovery 
often takes several months after dose modification 
or discontinuation. An increased incidence of her-
pes zoster reactivation has been reported, requiring 
acyclovir prophylaxis in all patients receiving 
bortezomib.67
Based on clinical trial data, HDAC inhibitors are 
generally well tolerated, but there have been reports 
of various different toxicities, such as reversible QT 
prolongation, pericardial effusion, hypokalemia and 
thrombocytopenia.68,69
supportive care
Considerable progress has been made for patients 
with MM in terms of supportive and palliative care. 
These measures can improve their quality of life 
(QoL) when integrated with conventional medical 
treatment.
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Approximately 85% of patients develop bone dis-
ease manifesting as osteopenia, osteolytic lesions and 
related complications, all of which reduce their per-
formance status and QoL.70 Patients should be treated 
with analgesics such as acetaminophen, whereas non 
steroidal anti-inflammatory drugs should be avoided 
because they can affect renal function. Opioids should 
be considered when patients fail to respond to first-
step therapy. Local radiotherapy can also relieve the 
pain of skeletal disease and may palliate soft tissue 
disease.71
Also, bisphosphonates can help in the management 
of bone pain in MM patients and can help in 
preventing occurrence of new bone lesions and 
pathological fractures.72,73 Moreover, there is evi-
dence that zoledronic acid may affect OS and PFS, 
probably interfering with the MM microenvironment 
in BM.73
Blood and platelet transfusions can help maintain 
the QoL by relieving exertional dyspnoea and pre-
venting bleeding, even when a patient is approaching 
the terminal stage of the disease.
Treatment strategies  
and patients preference
The clinical picture of relapsed/refractory MM 
ranges from an asymptomatic form to a very aggres-
sive disease. Relapsed/refractory patients with MM 
should be treated at the appearance of the typical 
clinical manifestations of MM, which are summa-
rized by the CRAB symptoms (elevated Calcium, 
Renal impairment, Anemia, and Bone lesions), or 
when monoclonal protein in serum or urine has a sig-
nificant growth. (Monoclonal spike .1 g/dL, Bence 
Jones protein [BJP] . 500 mg/day, or serum free light 
chain .200 mg/dL).
There are still no standard therapies for relapsed/
refractory MM, and treatment remains a challenge, 
especially in the case of patients who already received 
several lines of therapies.70 Nevertheless, the use of 
IMIDs and proteasome inhibitors has led to deepest 
and longest remissions in front line therapies, allow-
ing patients to obtain longer event-free survivals. 
The lesson from clinical trials shows that the new 
agents work also in relapsed/refractory MM patients, 
thus rendering crucial the sequence and the timing 
of drug choosing. In addition, various disease- and 
patient-related factors, as well as pharmacological 
characteristics of antimyeloma agents, should be con-
sidered for therapeutic management. The quality and 
duration of response to previous therapies and the 
aggressiveness of the relapse are important disease-
related factors and represent key points in treatment 
strategies. Deep and prolonged responses are more 
likely in patients with a late relapse (after a remission 
of .12 months) than in those relapsing early (a remis-
sion of ,6 months). If the relapse occurs after a long 
remission and treatment-free period, it is possible to 
consider repeating the same treatment,70–74 but if it 
occurs earlier (6–12 months) or while the patient is 
still undergoing treatment (which indicates aggres-
sive, relapsed and refractory disease), the use of an 
alternative regimen should be considered. In addi-
tion, the presence of clinical risk factors such as cyto-
genetic abnormalities may indicate high-risk disease, 
which requires a different approach from that used 
in ‘slowly’ relapsing patients. Bortezomib can over-
come the poor prognosis of patients with unfavorable 
chromosomal abnormalities, such as the del(13q14) 
and t(4:14) mutations. There are also initial data sug-
gesting that high doses of bortezomib-based treat-
ment may be effective in patients with the del (17p) 
mutation, which is usually associated with refractori-
ness to therapy.36
Patient-related factors include pre-existing tox-
icities, comorbidities, the quality of life, age and 
performance status. Some degree of renal impair-
ment frequently occurs in MM patients and, as many 
therapeutic agents are renally excreted, this may 
affect drug pharmacokinetics and limit the choice. 
Among the new drugs, bortezomib and thalidomide 
are not renally excreted, which makes them better 
for patients with renal impairment than lenalido-
mide, which instead is renally excreted and therefore 
requires dose adjustments. Moreover, bortezomib has 
shown beneficial effects in patients with MM and 
renal insufficiency32,33 by rapidly reducing light chain 
production. On the contrary, as neither lenalidomide 
nor thalidomide are metabolized by the liver, they are 
more suitable for patients with impaired liver func-
tion than bortezomib.
The use of thalidomide and bortezomib can lead to 
neuropathy in up to 80% of previously treated patients, 
whereas neuropathy is less frequent in patients treated 
with lenalidomide-based regimens, thus making them 
a reasonable choice in patients with pre-existing neu-
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ropathies. Subcutaneous administration of bortezomib 
results in less polyneuropathy related symptoms, than 
intravenous infusion.75
Bortezomib alone has not been associated with 
any increase in VTE, and is therefore a good choice 
for patients with a history of thromboembolic events. 
Thalidomide or lenalidomide treatment generally 
requires appropriate anti-thrombotic prophylaxis. It 
is generally accepted that acetylsalicylic acid (ASA) 
is a good thromboprophylaxis in patients without a 
previous history of thrombotic events and with no 
thrombotic risk factors, whereas anti-coagulant pro-
phylaxis is mandatory for those patients who have 
previously experienced a thromboembolic event or 
who are at high thrombotic risk.61,62 The thrombo-
prophylaxis, with low molecular weight heparin, 
should be performed almost for 3 months before 
switching to aspirin, since thromboembolic events 
are more likely in the first three months of treatment 
with IMIDs.76 When an aggressive relapse occurs, 
patients whose performance status allows them to 
tolerate an aggressive treatment should be treated 
to obtain the deepest response in order to improve 
survival. Aggressive and rapid relapse requires an 
immediate treatment, which is likely a combination 
therapy including treatment with chemotherapy 
based regimens, chemotherapy in combination with 
novel agents (lenalidomide or bortezomib) or trans-
plant based regimen. In contrast, when the patient’s 
global health status does not allow them to tolerate 
an aggressive therapy, best supportive care should 
be considered in order to improve the quality of 
life.
The fact that one-third of MM patients are 75 years 
old or older at diagnosis raises some concerns about 
the tolerability and the toxicity of the treatment. 
Although age should not be considered an exclusion 
criterion for treatment, only a few clinical trials 
have investigated the safety and efficacy of drugs in 
elderly and/or frail patients. Modified treatment regi-
mens and dose reductions should be used to improve 
tolerability.
conclusions
Novel agents targeting the MM and its 
microenvironment such as thalidomide, lenalido-
mide and bortezomib have improved outcomes and 
extended survival in patients with relapsed and/or 
refractory MM. Several evidences have demonstrated 
that their usage at the time of a first relapse is linked 
with better outcomes rather than as salvage treatment 
after 2 or more previous therapies. Combination 
therapy using agents with different mechanisms of 
action is becoming an attractive means of increasing 
efficacy and/or overcoming resistance to standard 
treatment regimens. Other new agents are in clini-
cal development. Pomalidomide has led to encour-
aging results in heavily pre-treated patients. The 
oral histone deacetylase inhibitors panobinostat and 
vorinostat can synergistically enhance the cytotoxic 
activity of lenalidomide and bortezomib, and over-
come possible resistance. The second-generation 
proteasome inhibitor carfilzomib can be used as 
monotherapy and in combination with lenalidomide 
plus low-dose dexamethasone. Combined therapy 
can be used to prevent or overcome treatment resis-
tance, and increase the efficacy of standard treatment 
regimens.
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